EyePoint Pharmaceuticals (EYPT) Stock Forecast, Price & News

EyePoint Pharmaceuticals (NASDAQ:EYPT) Frequently Asked Questions

Is EyePoint Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EyePoint Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EyePoint Pharmaceuticals stock.
View analyst ratings for EyePoint Pharmaceuticals or view top-rated stocks.

When is EyePoint Pharmaceuticals' next earnings date?

EyePoint Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for EyePoint Pharmaceuticals.

How were EyePoint Pharmaceuticals' earnings last quarter?

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) posted its quarterly earnings results on Wednesday, May, 4th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.02. The company earned $9.29 million during the quarter, compared to analysts' expectations of $10.35 million. EyePoint Pharmaceuticals had a negative trailing twelve-month return on equity of 47.60% and a negative net margin of 174.09%. During the same period last year, the business earned ($0.50) EPS.
View EyePoint Pharmaceuticals' earnings history.

When did EyePoint Pharmaceuticals' stock split? How did EyePoint Pharmaceuticals' stock split work?

Shares of EyePoint Pharmaceuticals reverse split before market open on Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, December 9th 2020. An investor that had 100 shares of EyePoint Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for EYPT?

3 equities research analysts have issued twelve-month price objectives for EyePoint Pharmaceuticals' shares. Their forecasts range from $24.00 to $35.00. On average, they anticipate EyePoint Pharmaceuticals' stock price to reach $29.50 in the next year. This suggests a possible upside of 210.2% from the stock's current price.
View analysts' price targets for EyePoint Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are EyePoint Pharmaceuticals' key executives?

EyePoint Pharmaceuticals' management team includes the following people:

• Ms. Nancy S. Lurker, Pres, CEO & Director (Age 65, Pay $1.05M)
• Mr. George O. Elston, Chief Financial Officer (Age 57, Pay $692.6k)
• Dr. Jay S. Duker M.D., Chief Operating Officer (Age 63, Pay $28.23k)
• Dr. Dario A. Paggiarino, Sr. VP & Chief Medical Officer (Age 65, Pay $694.19k)
• Mr. David Scott Jones, Sr. VP & Chief Commercial Officer (Age 55, Pay $604.04k)
• Mr. Said Saim, Chief Technology Officer (Age 64)
• Mr. Ron I. Honig Esq., Chief Legal Officer & Company Sec.
• Mr. Michael Pine, Chief Corp. Devel. & Strategy Officer
• Ms. Jennifer Leonard, Chief People Officer & Sr. VP of IT
• Ms. Isabelle Lefebvre, Chief Regulatory Officer

Who are some of EyePoint Pharmaceuticals' key competitors?

Some companies that are related to EyePoint Pharmaceuticals include Pacific Biosciences of California (PACB), Cue Health (HLTH), Quanterix (QTRX), Bionano Genomics (BNGO), Nautilus Biotechnology (NAUT), Akoya Biosciences (AKYA), Berkeley Lights (BLI), Singular Genomics Systems (OMIC), Rapid Micro Biosystems (RPID), Harvard Bioscience (HBIO), Standard BioTools (LAB), Codex DNA (DNAY), IsoPlexis (ISO), Accelerate Diagnostics (AXDX) and Scientific Industries (SCND).
View all of EYPT's competitors.

What other stocks do shareholders of EyePoint Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other EyePoint Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Inovio Pharmaceuticals (INO), Verastem (VSTM), XOMA (XOMA), AcelRx Pharmaceuticals (ACRX), Catalyst Pharmaceuticals (CPRX), Progenics Pharmaceuticals (PGNX), Corbus Pharmaceuticals (CRBP) and Dynavax Technologies (DVAX).

What is EyePoint Pharmaceuticals' stock symbol?

EyePoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."

Who are EyePoint Pharmaceuticals' major shareholders?

EyePoint Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Suvretta Capital Management LLC (8.55%), BlackRock Inc. (4.48%), Vanguard Group Inc. (3.62%), Goldman Sachs Group Inc. (2.56%), Verition Fund Management LLC (1.34%) and State Street Corp (1.10%).
View institutional ownership trends for EyePoint Pharmaceuticals.

Which institutional investors are selling EyePoint Pharmaceuticals stock?

EYPT stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., and Simplex Trading LLC.
View insider buying and selling activity for EyePoint Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying EyePoint Pharmaceuticals stock?

EYPT stock was acquired by a variety of institutional investors in the last quarter, including Suvretta Capital Management LLC, Goldman Sachs Group Inc., Verition Fund Management LLC, BlackRock Inc., Dimensional Fund Advisors LP, Essex Investment Management Co. LLC, Vanguard Group Inc., and Northern Trust Corp.
View insider buying and selling activity for EyePoint Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of EyePoint Pharmaceuticals?

Shares of EYPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is EyePoint Pharmaceuticals' stock price today?

One share of EYPT stock can currently be purchased for approximately $9.51.

How much money does EyePoint Pharmaceuticals make?

EyePoint Pharmaceuticals has a market capitalization of $323.82 million and generates $35.31 million in revenue each year. The company earns $-58.42 million in net income (profit) each year or ($2.08) on an earnings per share basis.

How many employees does EyePoint Pharmaceuticals have?

EyePoint Pharmaceuticals employs 122 workers across the globe.

When was EyePoint Pharmaceuticals founded?

EyePoint Pharmaceuticals was founded in 1987.

What is EyePoint Pharmaceuticals' official website?

The official website for EyePoint Pharmaceuticals is eyepointpharma.com.

How can I contact EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The company can be reached via phone at (617) 926-5000, via email at [email protected], or via fax at 617-926-5050.